Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and Pharmacodynamics of Intranasal LMN-1001
NCT07852208Phase 1Not yet recruiting
- Sponsor
- Lumen Bioscience
- Start
- Nov 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1 trial of LMN-1001 in viral infection (5 arms), sponsored by Lumen Bioscience. Primary endpoints: Number of solicited Adverse Events and Serious Adverse Events at Day 14, Number of unsolicited Adverse Events and Serious Adverse Events at Day 14 and 25 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
LMN-1001
03
Conditions
viral infection
Beyond the preview
Go deeper on NCT07852208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07852208.